PD-1/PD-L1-IN-13

• UNSPSC Description:

  PD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC50 value of 10.2 nM. PD-1/PD-L1-IN-13 promots CD8+ T cell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse model[1].

• Target Antigen:

  PD-1/PD-L1

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pd-1-pd-l1-in-13.html

• Solubility:

  DMSO : 150 mg/mL (ultrasonic)

• Smiles:

  CC1=C(C=CC=C1C(F)(F)OC2=C(Cl)C=C(CN[C@@H]3C(O)O[C@H](CO)[C@@H](O)[C@@H]3O)C(OCC4=CC(C#N)=NC=C4)=C2)C5=CC=C(OCCO6)C6=C5

• Molecular Weight:

  726.12

• References & Citations:

  [1]Song Z, et al. Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage. J Med Chem. 2021;64(22):16687-16702.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2865841-81-0